We got here throughout a bullish thesis on Syndax Prescribed drugs, Inc. on BioEquity Watch’s Substack. On this article, we are going to summarize the bulls’ thesis on SNDX. Syndax Prescribed drugs, Inc.’s share was buying and selling at $20.67 as of January fifteenth.
Phovoir/Shutterstock.com
Syndax Prescribed drugs has transitioned right into a commercial-stage biotech anchored by two first-in-class accredited therapies, Revuforj (revumenib) and Niktimvo (axatilimab), every addressing areas of excessive unmet medical want. Revuforj is an oral Menin inhibitor accredited for relapsed or refractory acute leukemias with KMT2A rearrangements, the place disruption of the Menin–KMT2A interplay shuts down oncogenic gene expression and drives leukemic cell differentiation and loss of life.
Constructing on this approval, Syndax is pursuing growth into NPM1-mutant AML by way of a supplemental NDA supported by AUGMENT-101 information, whereas additionally advancing frontline mixture research that would meaningfully broaden its addressable market. Niktimvo, an anti-CSF-1R monoclonal antibody accredited for closely pretreated persistent graft-versus-host illness, targets macrophage-driven irritation and fibrosis, providing a differentiated mechanism versus present therapies. Its pipeline growth into IPF and mixture regimens in cGVHD additional extends its long-term potential.
Financially, Syndax is nicely capitalized, with roughly $518 million in money and investments as of Q2 2025. Revuforj is displaying robust early business traction, producing $28.6 million in quarterly web income with sequential development, whereas collaboration income from Incyte helps Niktimvo’s launch. Though the corporate stays loss-making attributable to elevated R&D and business spending, administration expects present money and rising revenues to fund operations via profitability.
Strategically, Syndax advantages from first-mover benefit in Menin inhibition, publicity to genetically outlined leukemia populations with restricted competitors, and income diversification throughout oncology and immune-mediated ailments. With late-2025 regulatory catalysts, increasing medical applications, and rising business adoption, Syndax presents a compelling long-term development alternative pushed by execution throughout its two cornerstone belongings.
Beforehand, we lined a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) by Magnus Ofstad in January 2025, which highlighted the corporate’s management in Duchenne muscular dystrophy, accelerating revenues, and acquisition enchantment. SRPT’s inventory worth has depreciated by roughly 81.94% since our protection attributable to security issues and regulatory uncertainty round Elevidys. BioEquity Watch shares the same view however emphasizes on business execution and first-in-class hematology belongings at Syndax Prescribed drugs.
